Indication
Bronchiectasis
Bronchiectasis is a chronic pulmonary disorder of the respiratory system characterized by the permanent, abnormal dilation and structural destruction of the bronchial walls. Read more about Bronchiectasis
6 drugs 6 manufacturers
Drugs that treat it
Common Bronchiectasis therapies.
ACETYLCYSTEINE
ACETYLCYSTEINE
ACETYLCYSTEINE
ACETYLCYSTEINE
ACETYLCYSTEINE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonBronchiectasis is a chronic pulmonary disorder of the respiratory system characterized by the permanent, abnormal dilation and structural destruction of the bronchial walls.
Pathophysiologically, it arises from a self-perpetuating cycle of impaired mucociliary clearance, chronic neutrophilic airway inflammation, persistent bacterial infection, and progressive tissue remodeling.
It can affect pediatric or adult populations and frequently develops secondary to conditions such as severe respiratory infections, cystic fibrosis, primary ciliary dyskinesia, or underlying immune deficiencies.
Defining clinical features include a chronic cough productive of copious, often purulent sputum, recurrent infectious exacerbations, dyspnea, and progressive airflow obstruction.
- nih.gov
Bronchiectasis is a chronic pulmonary disorder of the respiratory system characterized by the permanent, abnormal dilation and structural destruction of the bronchial walls Pathophysiologically, it arises from a self-perpetuating cycle of impaired mucociliary clearance, chronic neutrophilic airway inflammation, persistent bacterial infection, and progressive tissue remodeling Defining clinical features include a chronic cough productive of copious, often purulent sputum, recurrent infectious exa...
- nih.gov
Bronchiectasis is a chronic pulmonary disorder of the respiratory system characterized by the permanent, abnormal dilation and structural destruction of the bronchial walls Defining clinical features include a chronic cough productive of copious, often purulent sputum, recurrent infectious exacerbations, dyspnea, and progressive airflow obstruction
- nih.gov
Pathophysiologically, it arises from a self-perpetuating cycle of impaired mucociliary clearance, chronic neutrophilic airway inflammation, persistent bacterial infection, and progressive tissue remodeling It can affect pediatric or adult populations and frequently develops secondary to conditions such as severe respiratory infections, cystic fibrosis, primary ciliary dyskinesia, or underlying immune deficiencies
- nih.gov
It can affect pediatric or adult populations and frequently develops secondary to conditions such as severe respiratory infections, cystic fibrosis, primary ciliary dyskinesia, or underlying immune deficiencies
- medlineplus.gov
Defining clinical features include a chronic cough productive of copious, often purulent sputum, recurrent infectious exacerbations, dyspnea, and progressive airflow obstruction
Personalize your experience
Follow Bronchiectasis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.